Chemotherapy-Induced Peripheral Neuropathy Market: Key Developments and Opportunities
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Is The Estimated Market Size Of The Chemotherapy Induced Peripheral Neuropathy Treatment Market In 2026, And How Will Its Value Evolve By 2030?
The market size for chemotherapy-induced peripheral neuropathy treatment has experienced strong growth in recent years. It is projected to expand from $1.75 billion in 2025 to $1.86 billion by 2026, at a compound annual growth rate (CAGR) of 6.2%. This historical growth can be attributed to the increasing use of neurotoxic chemotherapy agents, rising cancer survival rates, growing recognition of chemotherapy side effects, the availability of symptomatic treatment options, and the expansion of oncology care infrastructure.
The chemotherapy induced peripheral neuropathy treatment market size is anticipated to see substantial expansion in the coming years. It is projected to grow to $2.37 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 6.2%. The increase during the forecast period can be attributed to heightened investment in targeted neuropathy therapies, an escalating focus on personalized oncology supportive care, the broadening of clinical trials for CIPN drugs, a rising demand for quality-of-life improving treatments, and advancements in biomarker-based diagnosis. Key trends for the forecast period include an intensified focus on neuroprotective drug development, a rising adoption of combination therapy approaches, a growing emphasis on early diagnosis and symptom management, the expansion of personalized treatment protocols, and increased clinical research on CIPN management.
Access Your Free Sample Report For In-Depth Market Analysis:
Which Important Drivers Are Guiding The Chemotherapy Induced Peripheral Neuropathy Treatment Market Growth?
The rising incidence of cancer is anticipated to drive expansion in the chemotherapy-induced peripheral neuropathy treatment market in the future. Cancer, a condition marked by the unchecked multiplication and dissemination of atypical cells throughout the body, often necessitates chemotherapy, which can lead to chemotherapy-induced peripheral neuropathy, a possible adverse reaction associated with specific chemotherapy medications. Therefore, the market for treating this condition is poised for growth due to the global increase in cancer diagnoses. For example, data from July 2024, provided by the Australian Institute of Health and Welfare, an Australia-based government agency, indicated that approximately 165,000 Australians received a new cancer diagnosis in 2023, translating to more than 450 daily cases, with males accounting for roughly 55% of these new diagnoses. Consequently, the expanding occurrence of cancers is fueling the development of the chemotherapy-induced peripheral neuropathy treatment market.
How Are Segments Identified Within The Chemotherapy Induced Peripheral Neuropathy Treatment Market Segment Framework?
The chemotherapy induced peripheral neuropathy treatment market covered in this report is segmented –
1) By Drug Class: Nerve Protective Therapy, Anti-Inflammatory Therapy, Neurotransmitter Based Therapy, Antioxidant, Other Drug Classes
2) By Treatment: Medication, Therapy, Other Treatments
3) By Drug Type: Branded, Generic
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacies, Other Distribution Channels
5) By End-User: Hospitals, Research Institutes, Specialty Clinics
Subsegments:
1) By Nerve Protective Therapy: Vitamin B Complex, Alpha-Lipoic Acid, Acetyl-L-Carnitine
2) By Anti-Inflammatory Therapy: Corticosteroids, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
3) By Neurotransmitter Based Therapy: Gabapentin, Pregabalin, Duloxetine
4) By Antioxidant: N-acetylcysteine, Glutathione, Coenzyme Q10
5) By Other Drug Classes: Topical Treatments, Opioids, Herbal Remedies
What Trends Are Influencing The Evolution Of The Chemotherapy Induced Peripheral Neuropathy Treatment Market?
Leading firms within the chemotherapy-induced peripheral neuropathy treatment market are prioritizing the development of novel products to enhance their capabilities and maintain their competitive standing. As an example, AlgoTx, a clinical-stage company dedicated to managing complex pain, announced in March 2023 that the FDA had approved the Investigational New Drug Application (IND) for ATX01, which is their Phase 2 first-in-class candidate. This breakthrough treatment is designed for those suffering from erythromelalgia. Concurrently, initial patients have been randomized into the ATX01 for the Pain of Chemotherapy (ACT) study, which focuses on chemotherapy-induced peripheral neuropathy (CIPN). The FDA has granted fast-track designation to both of these programs.
Who Are The Companies Competing Within The Chemotherapy Induced Peripheral Neuropathy Treatment Market?
Major companies operating in the chemotherapy induced peripheral neuropathy treatment market are Midatech Pharma PLC, Novartis AG, Hoffmann-La Roche Ltd., Lee’s Pharmaceutical Holdings Limited, RELIEF THERAPEUTICS Holding SA, WEX Pharmaceuticals Inc., MediciNova Inc., Solasia Pharma K.K., ESTEVE, Novaremed AG, MAKScientific LLC, Sova Pharmaceuticals Inc., Kineta Inc., Aptinyx Inc., Apexian Pharmaceuticals Inc., Alexion Pharmaceuticals Inc., Sanofi, Takeda Pharmaceutical Company Limited, Vertex Pharmaceuticals Incorporated, Abbott Laboratories, Acorda Therapeutics Inc., Galena Biopharma Inc., Incyte Corporation, ChromaDex Inc., Eurofins Advinus, Asahi Kasei Corporation, WinSanTor Inc., Apollo Endosurgery Inc.
Get The Full Chemotherapy Induced Peripheral Neuropathy Treatment Market Report:
Which Region Holds The Highest Market Share In The Chemotherapy Induced Peripheral Neuropathy Treatment Market?
North America was the largest region in the chemotherapy induced peripheral neuropathy treatment market in 2025. Asia-Pacific and Europe are expected to be the fastest-growing regions in the forecast period. The regions covered in the chemotherapy induced peripheral neuropathy treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Chemotherapy Induced Peripheral Neuropathy Treatment Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Chemotherapy Induced Peripheral Neuropathy Treatment Market 2026, By The Business Research Company
Neuropathic Pain Market Report 2026
https://www.thebusinessresearchcompany.com/report/neuropathic-pain-global-market-report
Peripheral Neuropathy Market Report 2026
https://www.thebusinessresearchcompany.com/report/peripheral-neuropathy-global-market-report
Diabetic Neuropathy Market Report 2026
https://www.thebusinessresearchcompany.com/report/diabetic-neuropathy-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
